Teva news from FierceBiotech
NewsAzilect data points to Parkinson's efficacy
Teva Pharmaceutical is touting the results of a late-stage study of Azilect, a treatment for Parkinson's disease. Researchers say the therapy hit all of its goals in the ADAGIO trial. Patients taking Read more...
Copaxone disappoints at higher dose
Shares of Israel's Teva Pharmaceuticals slid after the company announced that a late-stage trial of a higher dose of its MS drug Copaxone did not perform better than a standard dose. Read more...
Biotech's next big opportunity: Follow-ons?
Follow-on biologics are often cited as major long-term threat to the biotech industry, which so far has not had to face a future where generic therapies are allowed to slice and dice the market for Read more...
Follow-on legislation follows a twisted path in DC
BIO is toasting proposed new legislation that would provide more than 14 years of patent protection on a biologic. Needless to say, the generics crowd is just a tad disappointed by the bill, saying Read more...
Teva snaps up CoGenesys in $400M buyout
Teva has whetted at least part of its appetite for fresh acquisitions with the announcement this morning that it is buying CoGenesys for $400 million in cash. The Israeli generic drug company says Read more...
ALSO NOTED: Sucampo Pharma names new CEO; Genetic tests are going DTC at a fast pace; Panel: Give FDA power to recall; and much
> Teva and the Technion Israel Institute of Technology are exploring a pact to develop stem cell lines for research work. Read more...
Teva's lupus drug flunks Phase II
Teva says its Phase II trial for the experimental lupus drug edratide failed to hit its primary endpoint. The weekly therapy failed to cut the rate of disease activity after 26 weeks of treatments. Read more...
ALSO NOTED: Flamel inks licensing deal;Alfacell trial hits a milestone; and much more...
> France's Flamel Technologies gets an undisclosed upfront payment and a schedule of potential milestone payments after signing a licensing and development deal with Wyeth for using its technology Read more...
ALSO NOTED: Teva invests in stem cell start-up; Anacor files for IPO; Merrion sets terms; and much more...
> Teva is investing $1 million in the stem cell start-up Cell Cure Neurosciences. Report > Anacor Read more...
| Press ReleasesPRESS RELEASE: TEVA ANNOUNCES COURT OF APPEALS DENIES NOVARTIS' EMERGENCY MOTION ON GENERIC FAMVIR TEVA ANNOUNCES COURT OF APPEALS DENIES NOVARTIS' EMERGENCY MOTION ON GENERIC FAMVIR Jerusalem, Israel, September 28, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that Read more... PRESS RELEASE: Teva Announces Settlement of Generic Avandia, Avandamet, and Avandaryl Litigation with GlaxoSmithKline Teva Announces Settlement of Generic Avandia, Avandamet, and Avandaryl Litigation with GlaxoSmithKline JERUSALEM -- Teva Pharmaceutical Industries announced today that the District Court case has Read more... PRESS RELEASE: Teva Provides Update On Generic Neurontin Litigation Teva Provides Update On Generic Neurontin Litigation Jerusalem, Israel, September 21, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the United States Court of Read more... PRESS RELEASE: Teva Provides Update on Edratide for Systemic Lupus Erythematosus Teva Provides Update on Edratide for Systemic Lupus Erythematosus JERUSALEM -- Sep 19, 2007 - Teva Pharmaceutical Industries announced today that the Company's synthetic peptide, edratide (TV-4710), Read more... PRESS RELEASE: US federal appeals court temporarily stops Teva from selling its generic version of fAMVIR US federal appeals court temporarily stops Teva from selling its generic version of the Novartis medicine Famvir US Court of Appeals for the Federal Circuit issues order prohibiting Teva from Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets